Institutional Repository

Who Are at Most Risk to Develop Symptoms after SARS-CoV-2 Infection? Early Study in A Controlled Setting

Show simple item record

dc.contributor.author Abdella, Saro
dc.contributor.author Hussen, Alemayehu
dc.contributor.author Defar, Atkure
dc.contributor.author Feleke, Altay
dc.contributor.author Ahmad, Mahamed
dc.contributor.author Rafera, Hailu
dc.contributor.author Adane, Sisay
dc.contributor.author Kebede, Adisu
dc.contributor.author Melese, Daniel
dc.contributor.author Dillnesa, Enatenesh
dc.contributor.author Kassa, Munir
dc.contributor.author Kifle, Tsigereda
dc.contributor.author Seman, Yakob
dc.contributor.author Bekuretsion, Natnael
dc.contributor.author Demoz, Getachew
dc.contributor.author Gosa, Mikias
dc.contributor.author Kidane, Biruktawit
dc.contributor.author Zenamarkos, Hana
dc.contributor.author Seid, Sara
dc.contributor.author Nigatu, Frehiwot
dc.contributor.author Seifu, Albab
dc.contributor.author Tollera, Getachew
dc.contributor.author Tessema, Masresha
dc.date.accessioned 2023-02-06T12:11:16Z
dc.date.available 2023-02-06T12:11:16Z
dc.date.issued 2021-06-10
dc.identifier.citation Abdella S, Hussen A, Defar A, Feleke A, Ahmad M, Rafera H, et al. (2021) Who Are at Most Risk to Develop Symptoms after SARS-CoV-2 Infection? Early Study in A Controlled Setting. J Antivir Antiretrovir. 13: 225. en_US
dc.identifier.uri http://ephispace.ephi.gov.et/xmlui/handle/123456789/547
dc.description.abstract Background: The clinical spectrum of COVID-19 disease includes asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure. The level of illness is associated with various individual factors. Therefore, this study aimed to assess factors that are associated with the development of symptoms among COVID-19 positive cases in a selected isolation and treatment center in Addis Ababa, Ethiopia. Method: The study was conducted at Eka Kotebe General Hospital, COVID-19 Isolation and Treatment Center, Addis Ababa from May 11-24, 2020. All participants admitted to the center during the study period, 347 confirmed COVID-19 positive cases, were enrolled in the study. The dependent variable was having sign or symptom for COVID-19. Association of age, gender, Body Mass Index (BMI), blood type, comorbidities and history of travel with the presence of sign or symptoms was assessed. A logistic regression analysis was conducted to assess the associations after adjusting for selected covariates. Significant level for all variables was reported at 95% Confidence Interval. Results: A total of 347 laboratory confirmed positive COVID-19 cases (mean age 33.9 ± 13.5) were included in the analysis. The large proportion (66%) of the study participants were males. Overall, 24% of the participants admitted to the hospital had at least one sign or symptom for COVID-19. Cough, headache, fever, sore throat and muscle ache were the most reported signs and symptoms. Cancer and HIV/AIDS were the leading comorbidities that the study participants reported. After adjusting for important covariates, gender, blood type, comorbidity and travel history were found to be significantly associated with having sign or symptom while being COVID-19 positive. However, age, BMI and income had no association with being symptomatic following the contraction of the COVID-19 infection. Conclusion: Gender, blood group, comorbidities, travel history were found to be significantly associated with being symptomatic while having COVID-19 disease in Ethiopia. Age and BMI had no associations with developing COVID-19 sign or symptom. Closer monitoring and intensified prevention strategies to protect those who are highly likely to develop symptoms may help efficient use of scarce resources in the control of the pandemic. We recommend further study to elaborate on the cause of association and to advance the knowledge base available. en_US
dc.language.iso en en_US
dc.publisher EPHI en_US
dc.subject COVID-19 en_US
dc.subject PANDEMIC en_US
dc.subject ETHIOPIA en_US
dc.title Who Are at Most Risk to Develop Symptoms after SARS-CoV-2 Infection? Early Study in A Controlled Setting en_US
dc.type Journal Article en_US
ep.contributor.affiliation TB and HIV Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation Food Science and Nutrition Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation Health System and Reproductive Health Research Directorate, Ethiopian Public Health Institute, Addis Ababa en_US
ep.contributor.affiliation National Training Center, Ethiopian Health Institute, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation National Laboratories Capacity Building Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation MDU, Minister's Office, Ethiopian Ministry of Health, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation COVID-19 Strategic Leadership, Ethiopian Ministry of Health, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation Medical Services Director General Office, Ethiopian Ministry of Health, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation Department of Medical Services, Eka Kotebe General Hospital, COVID-19 Isolation and Treatment Center, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation Director’s Office, Primary Health Care, Addis Ababa, Ethiopia; en_US
ep.contributor.affiliation Operations Department, Enveritas, Addis Ababa, Ethiopia en_US
ep.contributor.affiliation Deputy Director General Office, Ethiopian Public Health Institute, Addis Ababa, Ethiopia en_US
ep.identifier.status Open Access en_US
ep.journal Journal of Antivirals and Antiretrovirals en_US
ep.issue 4 en_US
ep.volume 13 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account